Faeth Therapeutics (FTH) Non-Current Debt (2020 - 2021)

Faeth Therapeutics' (FTH) quarterly Non-Current Debt came in at $567000.0 in Q2 2021, little changed on a QoQ basis from $567000.0 in Q1 2021.

Faeth Therapeutics (FTH) Non-Current Debt (2020 - 2021) Analysis & Trends

Faeth Therapeutics (FTH) has 2 years of Non-Current Debt data on file, last reported at $567000.0 in Q2 2021.

Quarterly Non-Current Debt changed N/A year-over-year to $567000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $567000.0 (changed N/A YoY) and the FY2020 annual result came in at $567000.0, changed N/A from the prior year.
Non-Current Debt steadied at $567000.0 in Q2 2021, from $567000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $567000.0 in Q4 2020 to a low of $567000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	Faeth Therapeutics	180.89 Mn	180.89 Mn	-	-

Download Data